| Catalyst | Drug/Treatment | Stage | Probability of Approval | Description | Drug Type | Therapeutic Area | Source |
|---|---|---|---|---|---|---|---|
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology | ||
PDUFA 2026 | Phase 3 | -% | FDA review of the new drug application for the treatment of example condition. Read More | Small Molecule | Oncology |
Recent Updates
Recently added Catalysts
Pulmonx Corporation$1.54
+0.07 (+4.76%)
D 27Pipeline Score MedTech · Commercial
Market Cap
65.47 M
EPS
-1.29
P/E Ratio
-
Value Trade
622.62 K
SEC Financials
Q1 2026Dilution Risk
35%Revenue
20.59 M
R&D Expenses
4.90 M
Operating CF
-10.10 M
Total Assets
119.97 M
Total Liabilities
74.20 M
Equity
45.76 M
D/E Ratio
12,345
16.54 %
Week
15.67 %
1 Month
8.39 %
3 Month
17.42 %
6 Month
-96.18 %
5 Year
-96.13 %
All Time
Cash Data
Cash Position
61.57 M
Monthly Burn
3.37 M
Runway
16.3 mo
Burn Trend
SEC Filing
May 4, 2026
Overview
Volume
206.57 K
52 Week Range
1.13 - 3.88
% held by Insiders
10.84 %
% held by Institutions
75.81 %
Enterprise Value
59.93 M
Total Shares
42.25 M
Short %
6.01 %
Float Shares
39.12 M
Company Description
locked
Upcoming Catalyst
Drug Pipeline Intelligence
D27
Pipeline Score $2M
Pipeline ValueValuation Signal
1
Drugs Scored0.1x
rNPV / MCap Top 29%
Micro Cap (rank 648 of 911)
Percentile RankPulmonx Corporation faces pipeline headwinds (27/100), with $38M risk-adjusted pipeline value, led by Chartis System in Bronchoscopy (Phase 1).
Showing 1 of 1 assets
| Drug | Indication | Phase | NCT ID | PTRS | rNPV | Status | Enrollment | Velocity | Design | Completion | ML Signal | Last Change |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Chartis System Unknown | Bronchoscopy | Phase 1 | NCT00684684 | 8% | $38M | COMPLETED | 18 | - | - | Nov 1, 2008 | - | Jan 22, 2009 |
Clinical Trial Results
| Drug Name | Indications | Phase | Date | Trial Results Summary | Title | Source |
|---|---|---|---|---|---|---|
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement | |
Example Drug | Example indication for clinical evaluation | Phase 3 | 2025-12-01 | The study met its primary endpoint demonstrating statistically significant improvement. Read More | Phase 3 Study Results Announcement |
Inside Trades
YEARLY INSIDER TRANSACTIONS
Sector Avg.
INSIDERS
SOLDINSIDERS
BOUGHT
SOLDINSIDERS
BOUGHT
POSITIVE SENTIMENT Based on 22 Insiders Transactions
Hedge Funds
Shares Held
HEDGE FUNDS
SOLDHEDGE FUNDS
BOUGHT
SOLDHEDGE FUNDS
BOUGHT
POSITIVE SENTIMENT Based on 27 hedge funds in the last quarter
18 buying (3 new)·9 selling (1 exited)·2 unchanged
Hedge Funds invested in LUNG
| HedgeFund Name ( 3 ) | % of Portfolio | Current MV - | Shares Owned - | Activity Avg Price $0 |
|---|---|---|---|---|
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K | |
Example Capital Management | 2.5 % | 15.00 M | 250.00 K |
LUNG Institutional Ownership Trends
Current Insider %
5.20%
—+0.00%
Current Institutional %
62.40%
—+0.00%
Total Ownership
67.60%
Insider + Institutional
Data Points
1
1 Ticker(s)
Option Chain Statistics
| Expiration | Volume | Open Interest | Implied Volatility Calls | Implied Volatility Puts | ||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Calls | Puts | Put-Call Ratio | Calls | Puts | Put-Call Ratio | IV | OiWaIv | VWaIv | IV | OiWaIv | VWaIv | |
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
| 2026-07-17 | 0 | 0.00 | 0 | 0 | - | - | - | - | - | - | ||
Option Chain
| Calls | Strike | Puts | ||||
|---|---|---|---|---|---|---|
| Last Price | Volume | Open Interest | Last Price | Volume | Open Interest | |
| No data available | ||||||
Open interest
Today's Open Interest
1.00 M
Put-Call Ratio
1.1
Put Open Interest
480.00 K
Call Open Interest
520.00 K
Open Interest Avg (30-day)
900,000
Today vs Open Interest Avg (30-day)
11.11%
Option Volume
Today's Volume
750.00 K
Put-Call Ratio
0.95
Put Volume
360.00 K
Call Volume
390.00 K
Volume Avg (30-day)
800,000
Today vs Volume Avg (30-day)
-6.25%
Company News
LUNGThe preliminary, unaudited revenue results described in this press release are estimates only and are subject to revision until the Company reports its full financial results for the quarter ended
Pulmonx Corporation announced the reappointment of Glen French as President and CEO alongside Derrick Sung as COO and CFO as part of a management transition. The company provided a preliminary revenue estimate of approximately $21.5 million for the third quarter of 2025 while rescheduling the official earnings call to November 12, 2025. The resignations of former executives Steve Williamson and Mehul Joshi were confirmed, but the company emphasized that these resignations were not due to disagreements. The company aims to stabilize and enhance shareholder value moving forward.
Read more →LUNG▼ -6.8%on this news
Pulmonx Announces Appointment of Mehul Joshi as Chief Financial Officer Redwood City, CA
Pulmonx Corporation has appointed Mehul Joshi as Chief Financial Officer, effective April 3, 2024. Joshi succeeds John McKune, who served as Interim CFO since October 2023. With over 30 years of experience in finance, Joshi aims to leverage his skills to advance Pulmonx's growth strategies, specifically in expanding access to the company's Zephyr Valve treatment for patients with severe emphysema. The transition signifies Pulmonx's commitment to strengthening its leadership team during a pivotal time for the company.
Read more →LUNGPulmonx Announces CFO Transition and Record Preliminary Third Quarter 2023 Revenue Derrick Sung steps down from his position as Chief Financial Officer to pursue another opportunity; John McKune appointed Interim Chief F
Pulmonx Corporation announced a transition in its Chief Financial Officer position, with Derrick Sung stepping down to pursue another opportunity. John McKune has been appointed as Interim CFO to ensure a smooth transition. The company also revealed preliminary third quarter 2023 revenue of approximately $17.6 million, reflecting a 30% increase from the same period last year. The final financial results will be reported at a conference call scheduled for October 30, 2023.
Read more →Competitive Position
How LUNG ranks across every disease it competes inCompetitive Position is a premium feature
See how LUNG ranks against every competitor across each disease it develops in: phase, best drug, trials and likelihood of approval.
Start free trial